- TheStreet.com•9 hours ago
The drug company maintained its 2017 guidance, but sales of two of its key drugs registered disappointing results, and shares were down in after-hours trading 3%.
- Barrons.com•10 hours ago
With companies like Under Armour (UAA), MGM Resorts International (MGM), and United Parcel Service (UPS) reporting tomorrow, we thought we'd get a jump start on the stocks moving after today's close: Amgen ...
- Reuters•10 hours ago
Sales of Enbrel, faced with increased competition and slowing growth in the rheumatology and dermatology sectors, dropped 15 percent to $1.18 billion, below Wall Street estimates of about $1.38 billion. Enbrel has traditionally been a growth driver for Amgen, although the company had cautioned that pricing pressure would likely hit the franchise this year. It's in decline," said Cowen and Co analyst Eric Schmidt.
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||159.05 x 300|
|Ask||160.39 x 100|
|Day's Range||164.34 - 165.40|
|52 Week Range||133.64 - 184.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.08|
|Dividend & Yield||4.60 (2.84%)|
|1y Target Est||N/A|